Evaluation of Submucosal or Lymphovascular Invasion Detection Rates in Early Gastric Cancer Based on Pathology Section Interval.

Endoscopic submucosal dissection Lymphovascular invasion Stomach neoplasm Submucosal invasion

Journal

Journal of gastric cancer
ISSN: 2093-582X
Titre abrégé: J Gastric Cancer
Pays: Korea (South)
ID NLM: 101559430

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 30 12 2019
revised: 14 03 2020
accepted: 19 03 2020
entrez: 30 6 2020
pubmed: 1 7 2020
medline: 1 7 2020
Statut: ppublish

Résumé

The guidelines for pathological evaluation of early gastric cancer (EGC) recommend wider section intervals for surgical specimens (5-7 mm) than those for endoscopically resected specimens (2-3 mm). Studies in surgically resected EGC specimens showed not negligible lymph node metastasis risks in EGCs meeting the expanded criteria for endoscopic submucosal dissection (ESD). This retrospective study included 401 EGC lesions with an endoscopic size of ≤ 30 mm detected in 386 patients. Pathological specimens obtained by ESD or surgery were cut into 2-mm section intervals for reference. Submucosal or lymphovascular invasion (LVI) was evaluated arbitrarily in 4- or 6-mm section intervals. McNemar's tests compared the differences between submucosal and LVI. Submucosal invasion was detected in 29.2% (117/401) and LVI in 9.5% (38/401) at 2-mm interval. The submucosal invasion detection rates in 4-mm intervals decreased to 88.0% or 90.6% (both P<0.001), while the LVI detection rates decreased to 86.8% or 57.9% (P=0.025 and P<0.001, respectively). In 6-mm intervals, the submucosal and LVI detection rates decreased further to 72.7-80.3% (P<0.001 for all three sets) and 55.3-63.2% (P<0.001 for all three sets), respectively. Among 150 out-of-indication cases at 2-mm interval, 4-10 (2.7%-6.7%) at 4-mm intervals, and 10-17 (6.7%-11.3%) at 6-mm intervals were misclassified as lesions meeting the curative resection criteria due to the underestimation of submucosal or LVI. After ESD, the 2-mm wide section interval was suitable for the pathological evaluation of focal submucosal or LVI. Thus, if an EGC lesion meets the expanded criteria for the ESD specimen pathological evaluation, it could be safely followed up.

Identifiants

pubmed: 32596000
doi: 10.5230/jgc.2020.20.e14
pmc: PMC7311219
doi:

Types de publication

Journal Article

Langues

eng

Pagination

165-175

Informations de copyright

Copyright © 2020. Korean Gastric Cancer Association.

Déclaration de conflit d'intérêts

Conflict of Interest: No potential conflict of interest relevant to this article was reported.

Références

Gut. 2009 Mar;58(3):331-6
pubmed: 19001058
Oncol Rep. 2011 Jun;25(6):1589-95
pubmed: 21455589
J Gastroenterol Hepatol. 2011 May;26(5):884-7
pubmed: 21198830
J Gastric Cancer. 2012 Jun;12(2):88-98
pubmed: 22792521
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1763-1769
pubmed: 30471457
Am J Gastroenterol. 2016 Feb;111(2):240-9
pubmed: 26782817
Surg Endosc. 2015 Jun;29(6):1476-83
pubmed: 25249150
Clin Endosc. 2017 Mar;50(2):170-178
pubmed: 27157856
Gastrointest Endosc. 2015 Feb;81(2):333-41.e1
pubmed: 25281498
Gastric Cancer. 2017 Jan;20(1):1-19
pubmed: 27342689
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
Gastrointest Endosc. 2018 Feb;87(2):338-347
pubmed: 28966062
J Gastric Cancer. 2019 Mar;19(1):1-48
pubmed: 30944757
Dig Endosc. 2016 Jan;28(1):3-15
pubmed: 26234303
Gut Liver. 2018 Jul 15;12(4):402-410
pubmed: 29588436
Gastric Cancer. 2012 Apr;15(2):221-5
pubmed: 22083418
Gastrointest Endosc. 2018 Dec;88(6):912-918
pubmed: 30053392
Gastric Cancer. 2010 Nov;13(4):267-70
pubmed: 21128064
Gastric Cancer. 2008;11(3):134-48
pubmed: 18825308
J Biopharm Stat. 2001 Feb-May;11(1-2):23-33
pubmed: 11459440
Gastric Cancer. 2015 Jan;18(1):188-92
pubmed: 24477418
Surg Endosc. 2019 Jan;33(1):26-32
pubmed: 30298447
Gut Liver. 2017 May 15;11(3):383-391
pubmed: 28096520
Endoscopy. 2015 Apr;47(4):293-301
pubmed: 25625697
Gastric Cancer. 2016 Jul;19(3):860-8
pubmed: 26304170
Gastric Cancer. 2000 Dec;3(4):219-225
pubmed: 11984739
Gastrointest Endosc. 2011 Sep;74(3):485-93
pubmed: 21741645
Gastric Cancer. 2006;9(4):295-302
pubmed: 17235632

Auteurs

Young-Il Kim (YI)

Center for Gastric Cancer, National Cancer Center, Goyang, Korea.

Myeong-Cherl Kook (MC)

Center for Gastric Cancer, National Cancer Center, Goyang, Korea.

Jee Eun Choi (JE)

Center for Gastric Cancer, National Cancer Center, Goyang, Korea.

Jong Yeul Lee (JY)

Center for Gastric Cancer, National Cancer Center, Goyang, Korea.

Chan Gyoo Kim (CG)

Center for Gastric Cancer, National Cancer Center, Goyang, Korea.

Bang Wool Eom (BW)

Center for Gastric Cancer, National Cancer Center, Goyang, Korea.

Hong Man Yoon (HM)

Center for Gastric Cancer, National Cancer Center, Goyang, Korea.

Keun Won Ryu (KW)

Center for Gastric Cancer, National Cancer Center, Goyang, Korea.

Young-Woo Kim (YW)

Center for Gastric Cancer, National Cancer Center, Goyang, Korea.

Il Ju Choi (IJ)

Center for Gastric Cancer, National Cancer Center, Goyang, Korea.

Classifications MeSH